Stock THTX THERATECHNOLOGIES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Theratechnologies Inc. Nasdaq

Equities

THTX

CA88338H7040

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 21:30:00 17/07/2024 BST 		5-day change 1st Jan Change
1.535 USD -2.69% Intraday chart for Theratechnologies Inc. +2.33% -5.25%
07-10 Theratechnologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2024 CI
07-10 Transcript : Theratechnologies Inc., Q2 2024 Earnings Call, Jul 10, 2024

Business Summary

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

Number of employees: 103

Sales per Business

CAD in Million2022Weight2023Weight Delta
Pharmaceutical
100.0 %
104 100.0 % 110 100.0 % +6.53%

Sales per region

CAD in Million2022Weight2023Weight Delta
United States
99.5 %
102 98.4 % 110 99.5 % +7.82%
Europe
0.3 %
2 1.6 % 0 0.3 % -76.34%
Canada
0.1 %
0 0.1 % 0 0.1 % +72.51%

Managers

Managers TitleAgeSince
Paul Lévesque CEO
 Chief Executive Officer 60 05/04/20
Philippe Dubuc DFI
 Director of Finance/CFO 57 23/02/16
Christian Marsolais CTO
 Chief Tech/Sci/R&D Officer 61 31/12/06
André Dupras HRO
 Human Resources Officer 60 30/05/21
Peter Kowal PRN
 Corporate Officer/Principal - 28/03/21
John Leasure PRN
 Corporate Officer/Principal - 28/03/21
Marie-Noël Colussi PRN
 Corporate Officer/Principal 55 28/02/97
Jocelyn Lafond LAW
 General Counsel 56 31/12/06

Members of the board

Members of the board TitleAgeSince
Andrew Molson BRD
 Director/Board Member 56 15/10/20
Frank Holler CHM
 Chairman 67 22/06/21
Dale MacCandlish-Weil BRD
 Director/Board Member 68 15/05/17
Dawn Svoronos BRD
 Director/Board Member 70 30/04/13
Paul Lévesque CEO
 Chief Executive Officer 60 05/04/20
Dale Weil
- -
Joseph Arena BRD
 Director/Board Member 69 12/05/21

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 45,980,768 40,271,933 ( 87.58 %) 0 87.58 %

Shareholders

NameEquities%Valuation
Investissement Québec
19.83 %
9,118,184 19.83 % 13 M $
Soleus Capital Management LP
10.44 %
4,801,376 10.44 % 7 M $
Soleus Capital Management LP (Investment Management)
10.44 %
4,801,376 10.44 % 7 M $
AIGH Capital Management LLC
8.102 %
3,725,204 8.102 % 5 M $
AIGH Capital Management LLC
8.089 %
3,719,302 8.089 % 5 M $
Nantahala Capital Management LLC
5.833 %
2,682,228 5.833 % 4 M $
Nantahala Capital Management LLC
5.833 %
2,682,228 5.833 % 4 M $
Morgan Stanley Capital Services LLC
4.898 %
2,252,232 4.898 % 3 M $
Morgan Stanley & Co. LLC
4.162 %
1,913,756 4.162 % 3 M $
Osaic Wealth, Inc.
0.4963 %
228,185 0.4963 % 319 459 $

Company contact information

Theratechnologies, Inc.

2015 Peel Street 11th floor

H3A 1T8, Montréal

+514 336 7800

http://www.theratech.com
address Theratechnologies Inc.(THTX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Biopharmaceuticals

Sales per region

Ratings for Theratechnologies Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.09 CAD
Average target price
8 CAD
Spread / Average Target
+282.78%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
CSL LIMITED Stock CSL Limited
+8.54% 100B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+11.97% 43.89B
BIOGEN INC. Stock Biogen Inc.
-11.76% 33.24B
UCB Stock UCB
+80.16% 29.36B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-12.20% 16.08B
INCYTE CORPORATION Stock Incyte Corporation
+4.00% 14.68B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-1.90% 12.87B
ALTEOGEN INC. Stock ALTEOGEN Inc.
+178.17% 10.55B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+3.52% 8.83B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. TH Stock
  4. THTX Stock
  5. Company Theratechnologies Inc.